UroGen Pharma's FDA nod for UGN-102 fuels recovery, but cash burn raises financing risks. Check out why I am maintaining my ...

The agency set aside concerns about UroGen’s approval trial to greenlight mitomycin intravesical solution for recurrent non-muscle invasive bladder cancer.

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder ...

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...

Urological cancers are malignancies that affect the organs of the urinary system and male reproductive system. Of these, bladder ...

The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk ...

Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder ...

Presents 18-month duration of response (DOR) data from the ENVISION study Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION Reports ENVISION and ...

Guideline recommendations for the management of NMIBC include trans-urethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one ...

Dr Murray on pembrolizumab counseling: “I split treatments into those we continue to put inside your bladder that patients are familiar with, and then pembrolizumab, which is FDA approved but ...

May is Bladder Cancer Awareness Month. It serves as a timely reminder to pay attention to subtle signs, especially blood in urine. Discover the risks, symptoms, and treatments surrounding bladder ...